# US 4,699,785 A · Cell line producing feline leukemia virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,699,785 A
- Document ID: US4699785A
- Status: Granted
- Kind: A
- Application number: 06/651,744
- Filed: 1984-09-18
- Granted: 1987-10-13
- Earliest claimed: 1984-09-18
- Assignees: The Regents of the University of California
- Inventors: Niels C. Pedersen
- Web page: https://patentgrep.com/patent/US4699785A

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 14/005: from viruses
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2740/13022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/13064: by serial passage
- Y10S 424/819: Viral vaccine for feline species, e.g. cats
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A novel feline fibroblastic cell line infected with Snyder-Theilen feline leukemia virus is provided. The cell line produces large amounts of FeLV when cultured in a medium free from serum supplement. The latter aspect is a substantial advantage since it reduces the expense of culturing and eliminates the need to separate serum from culture medium prior to preparing a vaccine. Feline fibroblastic cell line FF64/280 was deposited at the American Type Culture Collection on Apr. 17, 1984, and granted accession no. VR 2085.

## Claims

### Claim 1

A fibroblast cell line infected with Snyder-Theilen feline leukemia virus, designated A.T.C.C. accession no. VR 2085.

### Claim 2

A method for preparing a vaccine capable of protecting a cat against viremia resulting from infection by feline leukemia virus, said method comprising:
obtaining whole, live feline leukemia virus from a fibroblastic cell line infected with Snyder-Theilen feline leukemia virus, designated A.T.C.C. accession no. VR 2085;
inactivating the virus; and
combining the inactivated virus in a physiologically-acceptable carrier.

### Claim 3

A method for protecting a cat against viremia resulting from infection by feline leukemia virus, said method comprising administering to the cat a vaccine containing an amount of inactivated feline leukemia virus obtained from a cell line designated A.T.C.C. VR 2085, said amount being effective to elicit serum-neutralizing antibodies against the virus.

### Claim 4

A method for producing a multivalent feline vaccine, said method comprising a propagating one or more different feline viruses on feline fibroblastic cell line FF64/280, A.T.C.C. designation no. VR 2085 in a suitable culture medium, collecting the medium which pg,19 contains feline leukemia virus in addition to the propagated virus(es), and inactivating the viruses in the culture medium to provide the vaccine.

### Claim 5 (depends on 4)

A method as in claim 4, wherein the propagated virus(es) is at least one virus selected from the group consisting of feline calicivirus, feline panleukopenia virus, and feline herpes virus.

### Claim 6 (depends on 4)

A method as in claim 4, wherein the virsu(es) is inactivated by treatment with .beta.-propiolactone.